Ann: RELINT: FPH: Disclosure of Senior Managers Relevant Interests

• Release Date: 10/11/15 10:12
• Summary: RELINT: FPH: Disclosure of Senior Managers Relevant Interests
• Price Sensitive: No
• Download Document  13.78KB

					FPH
10/11/2015 10:12
RELINT
NOT PRICE SENSITIVE
REL: 1012 HRS Fisher & Paykel Healthcare Corporation Limited

RELINT: FPH: Disclosure of Senior Managers Relevant Interests

To NZX Limited; and
Name of listed issuer:  Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:  10-Nov-15
Date of last disclosure:   10-Sep-15

Director or senior manager giving disclosure
Full name(s):  DEBORAH ANNE BAILEY
Name of listed issuer: Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):  Not Applicable
Position held in listed issuer:  Vice President Human Resources

Summary of acquisition or disposal of relevant interest (excluding specified
derivatives)
Class of affected quoted financial products:   Ordinary Shares
Nature of the affected relevant interest(s):  Beneficial interest in shares
issued to a trustee under an Employee Share Scheme
For that relevant interest-
Number held in class before acquisition or disposal:  0
Number held in class after acquisition or disposal:  410
Current registered holder(s):  N/A
Registered holder(s) once transfers are registered:  Fisher & Paykel
Healthcare Employee Share Purchase Trustee Limited

Summary of acquisition or disposal of specified derivatives relevant interest
(if applicable)
Type of affected derivative:   Not Applicable
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of
underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically
settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration
payable under the derivative or the value of the derivative is affected by
the value of the underlying financial products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the
nature of the relevant interest in the derivative:

Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: One
Details of transactions requiring disclosure-
Date of transaction:  2-Nov-15
Nature of transaction:  New interest in shares issued to a trustee under an
Employee Share Scheme
Name of any other party or parties to the transaction (if known):
The consideration, expressed in New Zealand dollars, paid or received for the
acquisition or disposal. If the consideration was not in cash and cannot be
readily by converted into a cash value, describe the consideration:  NZ$2,337

Number of financial products to which the transaction related:  410 Ordinary
Shares
If the issuer has a financial products trading policy that prohibits
directors or senior managers from trading during any period without written
clearance (a closed period) include the following details--
Whether relevant interests were acquired or disposed of during a closed
period:  No
Whether prior written clearance was provided to allow the acquisition or
disposal to proceed during the closed period:  Not Applicable
Date of the prior written clearance (if any):  Not Applicable

Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products:
Nature of relevant interest:  "(a) Ordinary Shares
(b) Share Options
(c) Performance Share Rights"
For that relevant interest,-
Number held in class:  "(a) 24,846
(b) 181,000
(c) 33,300"
Current registered holder(s):  DEBORAH ANNE BAILEY
For a derivative relevant interest,-
Type of derivative:

Class of quoted financial products:
Nature of relevant interest:
For that relevant interest,-
Number held in class:
Current registered holder(s):
For a derivative relevant interest,-
Type of derivative:

Class of quoted financial products:
Nature of relevant interest:
For that relevant interest,-
Number held in class:
Current registered holder(s):
For a derivative relevant interest,-
Type of derivative:
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of
underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically
settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration
payable under the derivative or the value of the derivative is affected by
the value of the underlying financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the
nature of the relevant interest in the derivative:

Certification
I certify that, to the best of my knowledge and belief, the information
contained in this disclosure is correct and that I am duly authorised to make
this disclosure by all persons for whom it is made.

Name of listed issuer:  Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:  10-Nov-15
Date of last disclosure:   24-Sep-15

Director or senior manager giving disclosure
Full name(s):  ANTONY GEORGE BARCLAY
Name of listed issuer: Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):  Not Applicable
Position held in listed issuer:  Chief Financial Officer

Summary of acquisition or disposal of relevant interest (excluding specified
derivatives)
Class of affected quoted financial products:   Ordinary Shares
Nature of the affected relevant interest(s):  Beneficial interest in shares
issued to a trustee under an Employee Share Scheme
For that relevant interest-
Number held in class before acquisition or disposal:  0
Number held in class after acquisition or disposal:  410
Current registered holder(s):  N/A
Registered holder(s) once transfers are registered:  Fisher & Paykel
Healthcare Employee Share Trustee Limited

Summary of acquisition or disposal of specified derivatives relevant interest
(if applicable)
Type of affected derivative:   Not Applicable
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of
underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically
settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration
payable under the derivative or the value of the derivative is affected by
the value of the underlying financial products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the
nature of the relevant interest in the derivative:

Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: One
Details of transactions requiring disclosure-
Date of transaction:  2-Nov-15
Nature of transaction:  New issue of Ordinary Shares under Employee Share
Scheme
Name of any other party or parties to the transaction (if known):
The consideration, expressed in New Zealand dollars, paid or recieved for the
acquisition or disposal. If the consideration was not in cash and cannot be
readily by converted into a cash value, describe the consideration:  NZ$2,337

Number of financial products to which the transaction related:  410 Ordinary
Shares
If the issuer has a financial products trading policy that prohibits
directors or senior managers from trading during any period without written
clearance (a closed period) include the following details--
Whether relevant interests were aquired or disposed of during a closed
period:  No
Whether prior written clearance was provided to allow the aquisition or
disposal to proceed during the closed period:  Not Applicable
Date of the prior written clearance (if any):  Not Applicable

Summary of other relevant interests after acquisition or disposal:

Nature of relevant interest:  "(a) Ordinary Shares
(b) Share Options
(c) Performance Share Rights"
For that relevant interest,-
Number held in class:  "(a) 92,549
(b) 321,166
(c) 56,500 "
Current registered holder(s):  ANTONY GEORGE BARCLAY
Note: Ordinary Shares held by Fisher & Paykel Healthcare Employee Share
Purchase Trustee Limited (of which Antony George Barclay is a director) will
no longer be disclosed following the determination by the Company that such
holding does not constitute a relevant interest for Antony George Barclay.

For a derivative relevant interest,-
Type of derivative:
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of
underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically
settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration
payable under the derivative or the value of the derivative is affected by
the value of the underlying financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the
nature of the relevant interest in the derivative:

Certification
I certify that, to the best of my knowledge and belief, the information
contained in this disclosure is correct and that I am duly authorised to make
this disclosure by all persons for whom it is made.

Name of listed issuer:  Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:  10-Nov-15
Date of last disclosure:   1-Oct-15

Director or senior manager giving disclosure
Full name(s):  PAUL NIGEL SHEARER
Name of listed issuer: Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):  Not Applicable
Position held in listed issuer:  Senior VP Sales & Marketing

Summary of acquisition or disposal of relevant interest (excluding specified
derivatives)
Class of affected quoted financial products:   Ordinary Shares
Nature of the affected relevant interest(s):  Beneficial interest in shares
issued to a trustee under an Employee Share Scheme
For that relevant interest-
Number held in class before acquisition or disposal:  0
Number held in class after acquisition or disposal:  410
Current registered holder(s):  N/A
Registered holder(s) once transfers are registered:  Fisher & Paykel
Healthcare Employee Share Trustee Limited

Summary of acquisition or disposal of specified derivatives relevant interest
(if applicable)
Type of affected derivative:   Not Applicable
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of
underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically
settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration
payable under the derivative or the value of the derivative is affected by
the value of the underlying financial products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the
nature of the relevant interest in the derivative:

Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: One
Details of transactions requiring disclosure-
Date of transaction:  2-Nov-15
Nature of transaction:  New issue of Ordinary Shares under Employee Share
Scheme
Name of any other party or parties to the transaction (if known):
The consideration, expressed in New Zealand dollars, paid or recieved for the
acquisition or disposal. If the consideration was not in cash and cannot be
readily by converted into a cash value, describe the consideration:  NZ$2,337

Number of financial products to which the transaction related:  410 Ordinary
Shares
If the issuer has a financial products trading policy that prohibits
directors or senior managers from trading during any period without written
clearance (a closed period) include the following details--
Whether relevant interests were aquired or disposed of during a closed
period:  No
Whether prior written clearance was provided to allow the aquisition or
disposal to proceed during the closed period:  Not Applicable
Date of the prior written clearance (if any):  Not Applicable

Summary of other relevant interests after acquisition or disposal:

Nature of relevant interest:  "(a) Ordinary Shares
(b) Share Options
(c) Performance Share Rights"
For that relevant interest,-
Number held in class:  "(a) 411,579
(b) 548,000
(c) 79,500"
Current registered holder(s):  PAUL NIGEL SHEARER
For a derivative relevant interest,-
Type of derivative:
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of
underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically
settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration
payable under the derivative or the value of the derivative is affected by
the value of the underlying financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the
nature of the relevant interest in the derivative:

Certification
I certify that, to the best of my knowledge and belief, the information
contained in this disclosure is correct and that I am duly authorised to make
this disclosure by all persons for whom it is made.
End CA:00273120 For:FPH    Type:RELINT     Time:2015-11-10 10:12:20